The CDMO sector is seeing remarkable development, fueled by growing biopharmaceutical demand and a transition towards contracting of manufacturing processes. Key trends include a greater emphasis on advanced therapies such as genetic therapies, patient-specific treatments, and sterile formulations. This creates opportunities for contract manufactur